Astute Medical said it’s in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.
Funding Roundup
Histogenics files for $65m IPO
Histogenics filed for an initial public offering, aiming to raise up to $65 million as it begins Phase III testing of its knee cartilage product NeoCart.
The regenerative medicine company plans to list its shares on the NASDAQ exchange under the symbol HSGX.
HealthEdge raises $30m for health insurance software
It’s been 10 years since HealthEdge got its start and the healthcare software company is still standing. But that doesn’t mean it’s been standing still.
Irish startup Embo Medical gets $3.8m in seed funding
Nevro registers $100m IPO
Nevro Corp. said it plans to raise more than $100 million in an initial public offering of stock for its implantable spinal cord stimulation system to treat chronic pain.
Vital Therapies prices offering
Cohealo raisies $9 million in a Series A round | Medtech funding for the week of September 29, 2014
Cohealo reports $9m Series A round for medical device sharing software
September 29, 2014 by Alexander Soule
Second Sight Medical eyes $3m bridge to IPO
Second Sight Medical is looking to bridge the gap to its forthcoming initial public offering with a $3 million loan from iconic chairman Al Mann.
UCLA spinout NeuroSigma seeks $50m in IPO
NeuroSigma aims to reap as much as $50.2 million in its upcoming initial public offering for the UCLA spinout’s noninvasive system to treat drug-resistant epilepsy.
NeuroSigma plans to sell 3.6 million shares on the NASDAQ exchange for between $13 and $15 each, reserving the symbol NSIG, according to a regulatory filing.
EndoStim targets $36m IPO
EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize the system.
Acutus Medical pulls in $26M
Acutus Medical said it secured $26.2 million in new funding for the cardiac mapping technology it’s developing to image and map atrial fibrillation hotspots.